Skip to content

Improving Weight Loss Outcomes for Binge Eating Disorder.

Improving Weight Loss Outcomes for Binge Eating Disorder.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03712462
Enrollment
126
Registered
2018-10-19
Start date
2018-08-20
Completion date
2023-02-01
Last updated
2024-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Binge Eating, Binge-Eating Disorder, Eating Disorder, Weight Loss

Keywords

Eating Disorder, Binge Eating, Binge Eating Disorder, Weight Loss

Brief summary

This study aims to develop and evaluate the efficacy of a behavioral weight loss treatment approach for individuals with binge eating disorder to both reduce their binge eating behaviors and lose weight.

Detailed description

In the current study, we propose to (a) compare the efficacy of an acceptance-based behavioral treatment (ABBT) that targets both binge eating and weight loss in patients with binge eating disorder (BED) to a Standard Behavioral Weight Loss Treatment (SBT), (b) evaluate the extent to which ABBT and SBT target shared maintenance factors for binge eating and overeating episodes, and (c) assess whether treatment efficacy is moderated by baseline values of constructs targeted in ABBT. Our study will be the first to evaluate an ABBT for BED designed to 1) address maintenance factors that give rise to both binge eating episodes and overeating episodes without loss of control and 2) increase adherence to BWL prescriptions.

Interventions

BEHAVIORALAcceptance-Based Behavioral Weight Loss Therapy for BED

ABBT group therapy incorporates standard behavioral and acceptance-based strategies and was adapted to meet suit the unique needs of BED.

BEHAVIORALStandard Behavior Therapy

SBT group therapy will be adapted from the gold-standard standard behavioral therapy manuals used from previous weight loss studies.

Sponsors

Yale University
CollaboratorOTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
Drexel University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

The novel acceptance-based behavioral weight loss therapy is being compared to standard behavioral weight loss therapy for individuals with binge eating disorder.

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Meet the DSM-5 criteria for Binge Eating Disorder * Have a BMI range of 27-50kg/m2

Exclusion criteria

* are unable to fluently speak, write, and read English * are currently experiencing severe psychopathology that would limit their ability to engage in study (e.g., suicidality, substance use disorder, psychotic disorder) * are unable to engage in moderate physical activity (i.e., walk 2 blocks without rest) * have a medical condition (e.g., acute coronary syndrome, type I diabetes) that would pose a risk to the participant during intervention, cause a change in weight, or limit ability to comply with the recommendations of the program * Pregnant or planning to become pregnant in the next 2 years * Recently began a course of or changed the dosage of medication that can cause significant change in weight * Have a history of bariatric surgery * Have had weight loss of \> 5% in the past 6 months

Design outcomes

Primary

MeasureTime frameDescription
Weight LossChanges from baseline assessment (before beginning treatment), to post-treatment assessment (1 year after baseline assessment), to follow-up assessment (2 years after baseline assessment)Between-group changes in percent weight loss from baseline 1 month, 3 months, and 6 months into the study, at post-treatment (1 year after baseline) and at the one year follow-up assessment (2 years after the baseline).

Secondary

MeasureTime frameDescription
Eating Disorder Examination QuestionnaireBaseline, Post-Treatment (1 year after baseline), and 1 Year Follow-Up (2 years after baseline)The Eating Disorder Examination Questionnaire measures eating pathology. The EDE-Q yields four subscale scores: Restraint, Eating Concern, Shape Concern, and Weight Concern. The possible score range for each subscale is 0 to 6. The total score may also be reported (determined by averaging the subscale scores); the score range for the total score is also 0 to 6. For subscale scores and total score, higher scores indicate more severe pathology. The restraint sub-scale of the EDE-Q will be used to assess utilization of skills related to reducing dietary restraint. Assessing changes in EDE Global score.

Countries

United States

Participant flow

Participants by arm

ArmCount
ABBT Weight Loss Therapy for BED
Acceptance-Based Behavioral Weight Loss Therapy for BED Acceptance-Based Behavioral Weight Loss Therapy for BED: ABBT group therapy incorporates standard behavioral and acceptance-based strategies and was adapted to meet suit the unique needs of BED.
63
Standard Behavior Therapy
Standard Behavioral Weight Loss Therapy Standard Behavior Therapy: SBT group therapy will be adapted from the gold-standard standard behavioral therapy manuals used from previous weight loss studies.
63
Total126

Baseline characteristics

CharacteristicABBT Weight Loss Therapy for BEDStandard Behavior TherapyTotal
Age, Continuous51.56 years
STANDARD_DEVIATION 12.41
51.05 years
STANDARD_DEVIATION 11.6
51.30 years
STANDARD_DEVIATION 11.96
Baseline EDE Global Score2.29 scores on a scale
STANDARD_DEVIATION 0.68
1.72 scores on a scale
STANDARD_DEVIATION 0.76
2.01 scores on a scale
STANDARD_DEVIATION 0.72
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants1 Participants3 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
58 Participants54 Participants112 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
3 Participants8 Participants11 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants1 Participants2 Participants
Race (NIH/OMB)
Black or African American
16 Participants15 Participants31 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants3 Participants5 Participants
Race (NIH/OMB)
White
44 Participants44 Participants88 Participants
Region of Enrollment
United States
63 participants63 participants126 participants
Sex: Female, Male
Female
51 Participants49 Participants100 Participants
Sex: Female, Male
Male
10 Participants12 Participants22 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 630 / 63
other
Total, other adverse events
0 / 630 / 63
serious
Total, serious adverse events
0 / 630 / 63

Outcome results

Primary

Weight Loss

Between-group changes in percent weight loss from baseline 1 month, 3 months, and 6 months into the study, at post-treatment (1 year after baseline) and at the one year follow-up assessment (2 years after the baseline).

Time frame: Changes from baseline assessment (before beginning treatment), to post-treatment assessment (1 year after baseline assessment), to follow-up assessment (2 years after baseline assessment)

ArmMeasureGroupValue (MEAN)Dispersion
ABBT Weight Loss Therapy for BEDWeight Loss1 Month-2.13 percentage of weight lossStandard Deviation 3.68
ABBT Weight Loss Therapy for BEDWeight Loss6 Months-7.65 percentage of weight lossStandard Deviation 7.37
ABBT Weight Loss Therapy for BEDWeight LossBaseline0 percentage of weight lossStandard Deviation 0
ABBT Weight Loss Therapy for BEDWeight LossPost-Treatment-7.46 percentage of weight lossStandard Deviation 9.67
ABBT Weight Loss Therapy for BEDWeight Loss3 Months-5.46 percentage of weight lossStandard Deviation 5.41
ABBT Weight Loss Therapy for BEDWeight Loss1 Year Follow-Up-4.76 percentage of weight lossStandard Deviation 9.01
Standard Behavior TherapyWeight Loss3 Months-5.25 percentage of weight lossStandard Deviation 4.32
Standard Behavior TherapyWeight LossBaseline0 percentage of weight lossStandard Deviation 0
Standard Behavior TherapyWeight Loss1 Month-2.15 percentage of weight lossStandard Deviation 2.85
Standard Behavior TherapyWeight Loss1 Year Follow-Up-3.52 percentage of weight lossStandard Deviation 7.02
Standard Behavior TherapyWeight Loss6 Months-6.97 percentage of weight lossStandard Deviation 5.92
Standard Behavior TherapyWeight LossPost-Treatment-7.06 percentage of weight lossStandard Deviation 7.42
Secondary

Eating Disorder Examination Questionnaire

The Eating Disorder Examination Questionnaire measures eating pathology. The EDE-Q yields four subscale scores: Restraint, Eating Concern, Shape Concern, and Weight Concern. The possible score range for each subscale is 0 to 6. The total score may also be reported (determined by averaging the subscale scores); the score range for the total score is also 0 to 6. For subscale scores and total score, higher scores indicate more severe pathology. The restraint sub-scale of the EDE-Q will be used to assess utilization of skills related to reducing dietary restraint. Assessing changes in EDE Global score.

Time frame: Baseline, Post-Treatment (1 year after baseline), and 1 Year Follow-Up (2 years after baseline)

ArmMeasureGroupValue (MEAN)Dispersion
ABBT Weight Loss Therapy for BEDEating Disorder Examination QuestionnaireBaseline2.29 score on a scaleStandard Deviation 0.68
ABBT Weight Loss Therapy for BEDEating Disorder Examination QuestionnairePost-Treatment2.49 score on a scaleStandard Deviation 0.77
ABBT Weight Loss Therapy for BEDEating Disorder Examination Questionnaire1 Year Follow-Up1.50 score on a scaleStandard Deviation 0.7
Standard Behavior TherapyEating Disorder Examination QuestionnaireBaseline1.72 score on a scaleStandard Deviation 0.76
Standard Behavior TherapyEating Disorder Examination QuestionnairePost-Treatment1.49 score on a scaleStandard Deviation 0.78
Standard Behavior TherapyEating Disorder Examination Questionnaire1 Year Follow-Up1.60 score on a scaleStandard Deviation 0.81

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026